Home>>Signaling Pathways>> Tyrosine Kinase>> PDGFR>>AG-1295

AG-1295 Sale

(Synonyms: 酪氨酸磷酸化抑制剂AG1295,NSC 380341,Tyrphostin AG-1295) 目录号 : GC16235

A selective inhibitor of PDGF receptor kinase

AG-1295 Chemical Structure

Cas No.:71897-07-9

规格 价格 库存 购买数量
1mg
¥193.00
现货
5mg
¥612.00
现货
10mg
¥1,020.00
现货
25mg
¥2,331.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

IC50: 0.3-1 μM for PDGF receptor kinase in vitro and in Swiss 3T3 cells

AG-1295 is a potent and selective inhibitor of PDGF receptor kinase.

Protein tyrosine kinase (PTK) inhibitors are potential antiproliferative agents for diseases caused by the hyperactivity of PTKs. PTK inhibitors specific for platelet-derived growth factor (PDGF) receptor kinase could help in the treatment of restenosis, pulmonary fibrosis, atherosclerosis and gliomas.

In vitro: The previous study investigated the effect of PDGF receptor-beta (PDGFR-β) inhibition by AG-1295 on the osteogenic differentiation of the mouse pre-osteoblastic cell line MC3T3-E1. Results showed that AG-1295 could significantly increase the alkaline phosphatase (ALP) activity and enhance the formation of mineralized nodules dose-dependently. Moreover, the treatment with AG-1295 led to the up-regulated mRNA expression of the osteogenic marker genes collagen type I, runt-related transcription factor 2, osterix, tissue-nonspecific alkaline phosphatase, as well as osteocalcin. Consistent with its effect on osteoblast differentiation, AG-1295 was also able to significantly suppress the phosphorylation of Erk1/2 in MC3T3-E1 cells [1].

In vivo: A previous animal study was designed to evaluated the possible effects of AG1295 on the development of interstitial fibrosis in rats with unilateral ureteral obstruction, monitored by ED-A+ fibronectin expression, the number of macrophages. Results showed that the i.p.treatment with AG1295 at 12 mg/kg could significantly reduce interstitial fibrosis as verified by a smaller Sirius-Red stained area and also by a reduced number of macrophages, and by the ED-A+ fibronectin deposition and the number of cells positive for α-smooth muscle actin [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Zhang YY, Cui YZ, Luan J, Zhou XY, Zhang GL, Han JX.  Platelet-derived growth factor receptor kinase inhibitor AG-1295 promotes osteoblast differentiation in MC3T3-E1 cells via the Erk pathway. Biosci Trends. 2012 Jun;6(3):130-5.
[2] Ludewig D, Kosmehl H, Sommer M, Bhmer FD, Stein G.  PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res. 2000 Jan;299(1):97-103.

Chemical Properties

Cas No. 71897-07-9 SDF
别名 酪氨酸磷酸化抑制剂AG1295,NSC 380341,Tyrphostin AG-1295
化学名 6,7-dimethyl-2-phenyl-quinoxaline
Canonical SMILES CC1=CC2=NC=C(N=C2C=C1C)C3=CC=CC=C3
分子式 C16H14N2 分子量 234.3
溶解度 ≤5mg/ml in ethanol;2mg/ml in DMSO;2.5mg/ml in dimethyl formamide 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 4.268 mL 21.3402 mL 42.6803 mL
5 mM 0.8536 mL 4.268 mL 8.5361 mL
10 mM 0.4268 mL 2.134 mL 4.268 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置